Explore Rheumatoid Arthritis, The European and more!

Explore related topics

Making medical decisions without accountability  http://www.kevinmd.com/blog/2017/02/making-medical-decisions-without-accountability.html

Making medical decisions without accountability http://www.kevinmd.com/blog/2017/02/making-medical-decisions-without-accountability.html

<span class="entry-title">Potential Rheumatoid Arthritis Vaccine Gets Boost from NIH</span><span class="entry-subtitle">Niche analysis may move CEL-SCI's LEAPS immunotherapy platform more quickly into human trials</span>

<span class="entry-title">Potential Rheumatoid Arthritis Vaccine Gets Boost from NIH</span><span class="entry-subtitle">Niche analysis may move CEL-SCI's LEAPS immunotherapy platform more quickly into human trials</span>

Read more about Researchers compare effectiveness of oral versus subcutaneous methotrexate for early Rheumatoid Arthritis

Read more about Researchers compare effectiveness of oral versus subcutaneous methotrexate for early Rheumatoid Arthritis

Read more about RA Patients in Europe Welcome Cost-Effective Biosimilars and Urge Agencies to Mandate Biosimilar Use

Read more about RA Patients in Europe Welcome Cost-Effective Biosimilars and Urge Agencies to Mandate Biosimilar Use

Study Suggests Cannabanoid Balance as Treatment for Depression http://ireadculture.com/article-5284-cannabanoid-balance-as-treatment-for-depression.html?utm_content=buffer3af7d&utm_medium=social&utm_source=pinterest.com&utm_campaign=buffer

Study Suggests Cannabanoid Balance as Treatment for Depression http://ireadculture.com/article-5284-cannabanoid-balance-as-treatment-for-depression.html?utm_content=buffer3af7d&utm_medium=social&utm_source=pinterest.com&utm_campaign=buffer

Eli Lilly and Incyte Corporation recently announced novel data from the pivotal Phase 3 RA-BEACON global trial of baricitinib, a once-daily oral drug presently under regulatory review for moderate-to-severe rheumatoid arthritis (RA). The results, “Baricitinib in Patients with Refractory Rheumatoid Arthritis” published in the New England Journal of Medicine, revealed the study met its primary endpoint of improved American …

Eli Lilly and Incyte Corporation recently announced novel data from the pivotal Phase 3 RA-BEACON global trial of baricitinib, a once-daily oral drug presently under regulatory review for moderate-to-severe rheumatoid arthritis (RA). The results, “Baricitinib in Patients with Refractory Rheumatoid Arthritis” published in the New England Journal of Medicine, revealed the study met its primary endpoint of improved American …

Are offshore investments illegal? We look at the differences between tax avoidance and tax evasion.

Cipher Pharmaceuticals Acquires Canadian Rights To New Rheumatoid Arthritis Treatment Rheumatoid Arthritis News

Cipher Pharmaceuticals Acquires Canadian Rights To New Rheumatoid Arthritis Treatment Rheumatoid Arthritis News

<span class="entry-title">Novel Inhibitor for Autoimmune Diseases Moving to Phase 2 Trial</span><span class="entry-subtitle">Chi-Med's HMPL-523 thought to have potential as first-in-class compound targeting Syk</span>

<span class="entry-title">Novel Inhibitor for Autoimmune Diseases Moving to Phase 2 Trial</span><span class="entry-subtitle">Chi-Med's HMPL-523 thought to have potential as first-in-class compound targeting Syk</span>

Rheumatologists need to “get creative” while treating rheumatoid arthritis, according to Dr. Daniel Furst, a Carl Pearson Professor of Medicine and director of the Rheumatology Clinical Research Center at the University of California Los Angeles School of Medicine. To spur on creative therapeutic solutions for the disease, rheumatologists need to combine therapies to address patients with symptoms that are difficult to resolve.

Rheumatologists need to “get creative” while treating rheumatoid arthritis, according to Dr. Daniel Furst, a Carl Pearson Professor of Medicine and director of the Rheumatology Clinical Research Center at the University of California Los Angeles School of Medicine. To spur on creative therapeutic solutions for the disease, rheumatologists need to combine therapies to address patients with symptoms that are difficult to resolve.

Pinterest
Search